The "Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, ...

Techne, bioMerieux, Roche, Lonza Group, Miltenyi Biotec India and More Cell and Gene Therapy Manufacturing QC Market Cell and ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

At a Food and Drug Administration cell and gene therapy (CGT) roundtable last June, most speakers pushed for the agency to ...

The market size of CGT products is expected to continue to rise by 2031 and reach $63 billion. CGTs have yielded commercial gains for several pharma companies. For example, some of the top-selling CGT ...

Precision DNA editing gene therapy achieves deep remissions in aggressive leukemia previously considered incurable.

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...

In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control ...

Medicaid is doing a novel payment system for the new, promising and expensive sickle cell treatment. It may become a model ...

NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.

The government is using sickle cell treatments to test a new strategy: paying only if the therapies benefit patients. With ...